Zacks: Brokerages Anticipate Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Will Announce Earnings of -$2.26 Per Share

Brokerages expect Reata Pharmaceuticals, Inc. (NASDAQ:RETAGet Rating) to report earnings per share of ($2.26) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Reata Pharmaceuticals’ earnings. Reata Pharmaceuticals reported earnings per share of ($1.86) during the same quarter last year, which indicates a negative year-over-year growth rate of 21.5%. The company is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Reata Pharmaceuticals will report full year earnings of ($9.29) per share for the current fiscal year, with EPS estimates ranging from ($10.34) to ($8.04). For the next financial year, analysts forecast that the business will post earnings of ($7.56) per share, with EPS estimates ranging from ($8.26) to ($6.17). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETAGet Rating) last announced its earnings results on Monday, February 28th. The company reported ($2.35) earnings per share for the quarter, missing the consensus estimate of ($2.31) by ($0.04). Reata Pharmaceuticals had a negative net margin of 2,588.22% and a negative return on equity of 105.72%. The business had revenue of $0.93 million for the quarter, compared to the consensus estimate of $1.76 million. During the same quarter in the previous year, the company earned ($1.90) EPS.

A number of analysts recently weighed in on the company. The Goldman Sachs Group upgraded Reata Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $34.00 to $91.00 in a report on Thursday, March 24th. started coverage on shares of Reata Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $115.14.

RETA stock opened at $25.38 on Friday. The business’s 50-day moving average price is $32.50 and its two-hundred day moving average price is $47.56. Reata Pharmaceuticals has a 1-year low of $22.71 and a 1-year high of $153.41.

A number of large investors have recently added to or reduced their stakes in RETA. FourThought Financial LLC boosted its stake in Reata Pharmaceuticals by 58.0% during the third quarter. FourThought Financial LLC now owns 583 shares of the company’s stock worth $58,000 after buying an additional 214 shares during the period. Macquarie Group Ltd. raised its stake in Reata Pharmaceuticals by 60.1% in the 3rd quarter. Macquarie Group Ltd. now owns 594 shares of the company’s stock valued at $60,000 after purchasing an additional 223 shares during the last quarter. O Shaughnessy Asset Management LLC increased its stake in shares of Reata Pharmaceuticals by 6,360.0% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 646 shares of the company’s stock valued at $65,000 after acquiring an additional 636 shares during the last quarter. First Mercantile Trust Co. increased its stake in shares of Reata Pharmaceuticals by 20.6% during the 3rd quarter. First Mercantile Trust Co. now owns 721 shares of the company’s stock valued at $73,000 after acquiring an additional 123 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in Reata Pharmaceuticals in the 4th quarter worth approximately $97,000. 73.55% of the stock is currently owned by institutional investors.

Reata Pharmaceuticals Company Profile (Get Rating)

Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.

See Also

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with's FREE daily email newsletter.